About this Journal Submit a Manuscript Table of Contents
Evidence-Based Complementary and Alternative Medicine
Volume 2012 (2012), Article ID 149762, 11 pages
http://dx.doi.org/10.1155/2012/149762
Review Article

Traditional Chinese Medicine-Based Network Pharmacology Could Lead to New Multicompound Drug Discovery

1School of Basic Medical Sciences, Beijing University of Chinese Medicine, Beijing 100029, China
2Institute of Basic Research of Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China
3School of Chinese Medicine, Hong Kong Baptist University, Kowloon, Hong Kong
4Institute of Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, China

Received 24 September 2012; Accepted 18 October 2012

Academic Editor: Shao Li

Copyright © 2012 Jian Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Hood, J. R. Heath, M. E. Phelps, and B. Lin, “Systems biology and new technologies enable predictive and preventative medicine,” Science, vol. 306, pp. 640–643, 2004.
  2. K. I. Goh, M. E. Cusick, D. Valle, B. Childs, M. Vidal, and A. L. Barabasi, “The human disease network,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, pp. 8685–8690, 2007.
  3. T. Pawson and R. Linding, “Network medicine,” FEBS Letters, vol. 582, pp. 1266–1270, 2008.
  4. M. A. Yildirim, K. I. Goh, M. E. Cusick, A. L. Barabasi, and M. Vidal, “Drug-target network,” Nature Biotechnology, vol. 25, pp. 1119–1126, 2007.
  5. C. G. Wermuth, “Multitargeted drugs: the end of the “one-target-one-disease” philosophy?” Drug Discovery Today, vol. 9, no. 19, pp. 826–827, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. L. Hopkins, “Network pharmacology,” Nature Biotechnology, vol. 25, pp. 1110–1111, 2007.
  7. A. L. Hopkins, “Network pharmacology: the next paradigm in drug discovery,” Nature Chemical Biology, vol. 4, pp. 682–690, 2008.
  8. F. Sams-Dodd, “Target-based drug discovery: is something wrong?” Drug Discovery Today, vol. 10, no. 2, pp. 139–147, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Wang, X. Fan, H. Qu, X. Gao, and Y. Cheng, “Strategies and techniques for multi-component drug design from medicinal herbs and traditional Chinese medicine,” Current Topics in Medicinal Chemistry, vol. 12, no. 12, pp. 1356–1362, 2012.
  10. K. Lan and W. Jia, “An integrated metabolomics and pharmacokinetics strategy for multi-component drugs evaluation,” Current Drug Metabolism, vol. 11, pp. 105–114, 2010.
  11. X. Y. Tian and L. Liu, “Drug discovery enters a new era with multi-target intervention strategy,” Chinese Journal of Integrative Medicine. In press. View at Publisher · View at Google Scholar
  12. H. Jaques, “The polypill concept: the future,” European Heart Journal, vol. 32, pp. 2732–2733, 2011.
  13. K. M. Carey, M. R. Comee, J. L. Donovan, and A. Kanaan, “A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke,” The Annals of Pharmacotherapy, vol. 46, pp. 688–695, 2012.
  14. A. Lu, M. Jiang, C. Zhang, and K. Chan, “An integrative approach of linking traditional Chinese medicine pattern classification and biomedicine diagnosis,” Journal of Ethnopharmacology, vol. 141, no. 2, pp. 549–556, 2011.
  15. A. P. Lu and K. J. Chen, “Integrative medicine in clinical practice: from pattern differentiation in traditional Chinese medicine to disease treatment,” Chinese Journal of Integrative Medicine, vol. 15, no. 2, article 152, 2009.
  16. Y. T. He, Q. L. Zha, J. P. Yu, Y. Tan, C. Lu, and A. P. Lu, “Principal factor analysis of symptoms of rheumatoid arthritis and their correlations with efficacy of traditional Chinese medicine and Western medicine,” Journal of Chinese Integrative Medicine, vol. 6, pp. 32–36, 2008.
  17. C. H. Huang, L. Cong, J. Xie, B. Qiao, S. H. Lo, and T. Zheng, “Rheumatoid arthritis-associated gene-gene interaction network for rheumatoid arthritis candidate genes,” BMC Proceedings, vol. 3, supplement 7, p. S75, 2009.
  18. G. Wu, L. Zhu, J. E. Dent, and C. Nardini, “A comprehensive molecular interaction map for rheumatoid arthritis,” PLoS ONE, vol. 5, Article ID e10137, 2010.
  19. J. Zhao, P. Jiang, and W. Zhang, “Molecular networks for the study of TCM pharmacology,” Briefings in Bioinformatics, vol. 11, pp. 417–430, 2010.
  20. C. Lu, X. Niu, C. Xiao, et al., “Network-based gene expression biomarkers for cold and heat patterns of rheumatoid arthritis in traditional Chinese medicine,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 203043, 17 pages, 2012. View at Publisher · View at Google Scholar
  21. G. Chen, C. Lu, Q. Zha, et al., “A network-based analysis of traditional Chinese medicine cold and hot patterns in rheumatoid arthritis,” Complementary Therapies in Medicine, vol. 20, pp. 23–30, 2012.
  22. M. Jiang, C. Xiao, G. Chen, et al., “Correlation between cold and hot pattern in traditional Chinese medicine and gene expression profiles in rheumatoid arthritis,” Frontiers of Medicine, vol. 5, pp. 219–228, 2011.
  23. C. Lu, C. Xiao, G. Chen et al., “Cold and heat pattern of rheumatoid arthritis in traditional Chinese medicine: distinct molecular signatures indentified by microarray expression profiles in CD4-positive T cell,” Rheumatology International, vol. 32, no. 1, pp. 61–68, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. Y. Gu, C. Lu, Q. Zha, et al., “Plasma metabonomics study of rheumatoid arthritis and its Chinese medicine subtypes by using liquid chromatography and gas chromatography coupled with mass spectrometry,” Molecular BioSystems, vol. 8, pp. 1535–1543, 2012.
  25. H. van Wietmarschen, K. Yuan, C. Lu et al., “Systems biology guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients,” Journal of Clinical Rheumatology, vol. 15, no. 7, pp. 330–337, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Ma, C. Tan, H. Zhang, M. Wang, W. Ding, and S. Li, “Bridging the gap between traditional Chinese medicine and systems biology: the connection of Cold Syndrome and NEI network,” Molecular BioSystems, vol. 6, pp. 613–619, 2010.
  27. S. Li, Z. Q. Zhang, L. J. Wu, X. G. Zhang, Y. D. Li, and Y. Y. Wang, “Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network,” IET Systems Biology, vol. 1, pp. 51–60, 2007.
  28. M. Chen, L. Zhao, and W. Jia, “Metabonomic study on the biochemical profiles of a hydrocortisone-induced animal model,” Journal of Proteome Research, vol. 4, pp. 2391–2396, 2005.
  29. W. Lam, S. Bussom, F. Guan et al., “Chemotherapy: the four-herb Chinese medicine PHY906 reduces chemotherapy-induced gastrointestinal toxicity,” Science Translational Medicine, vol. 2, no. 45, Article ID 45ra59, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Wang, G. B. Zhou, P. Liu et al., “Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 12, pp. 4826–4831, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Jiang, W. Dai, S. Yan et al., “Potential biomarkers in the urine of myocardial infarction rats: a metabolomic method and its application,” Molecular BioSystems, vol. 7, no. 3, pp. 824–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Li, B. Zhang, D. Jiang, Y. Wei, and N. Zhang, “Herb network construction and co-module analysis for uncovering the combination rule of traditional Chinese herbal formulae,” BMC Bioinformatics, vol. 11, no. 11, article S6, 2010. View at Publisher · View at Google Scholar · View at Scopus
  33. J. van der Greef and R. N. McBurney, “Rescuing drug discovery: in vivo systems pathology and systems pharmacology,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 961–967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. L. Zhao, J. K. Nicholson, A. Lu, et al., “Targeting the human genome-microbiome axis for drug discovery: inspirations from global systems biology and traditional Chinese medicine,” Journal of proteome research, vol. 11, no. 7, pp. 3509–3519, 2012. View at Publisher · View at Google Scholar
  35. S. Zhao and R. Iyengar, “Systems pharmacology: network analysis to identify multiscale mechanisms of drug action,” Annual Review of Pharmacology and Toxicology, vol. 52, pp. 505–521, 2012.
  36. H. Z. Ye, C. S. Zheng, X. J. Xu, M. X. Wu, and X. X. Liu, “Potential synergistic and multitarget effect of herbal pair Chuanxiong Rhizome-Paeonia Albifora Pall on osteoarthritis disease: a computational pharmacology approach,” Chinese Journal of Integrative Medicine, vol. 17, pp. 698–703, 2011.
  37. L. B. C. Gao, J. Miao, T. Yong, and L. Aiping, “Functional networks for Salvia miltiorrhiza and Panax notoginseng in combination explored with text mining and bioinformatical approach,” Journal of Medicinal Plants Research, vol. 5, article 10, 2011.
  38. G. Chen and A. P. Lu, “Prediction of the mechanisms of salvia miltiorrhiza against atherosclerosis using text mining and network-based analysis,” Journal of Algorithms and Computational Technology, vol. 5, no. 1, pp. 139–144, 2011. View at Publisher · View at Google Scholar · View at Scopus
  39. http://www.ncbi.nlm.nih.gov/pubchem.
  40. B. Chen, D. Wild, and R. Guha, “PubChem as a source of polypharmacology,” Journal of Chemical Information and Modeling, vol. 49, no. 9, pp. 2044–2055, 2009. View at Publisher · View at Google Scholar · View at Scopus
  41. Q. Li, T. Cheng, Y. Wang, and S. H. Bryant, “PubChem as a public resource for drug discovery,” Drug Discovery Today, vol. 15, no. 23-24, pp. 1052–1057, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. Y. Pouliot, A. P. Chiang, and A. J. Butte, “Predicting adverse drug reactions using publicly available PubChem bioassay data,” Clinical Pharmacology and Therapeutics, vol. 90, no. 1, pp. 90–99, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. S. Li, L. Wu, and Z. Zhang, “Constructing biological networks through combined literature mining and microarray analysis: a LMMA approach,” Bioinformatics, vol. 22, no. 17, pp. 2143–2150, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Le Phillip, A. Bahl, and L. H. Ungar, “Using prior knowledge to improve genetic network reconstruction from microarray data,” In Silico Biology, vol. 4, no. 3, pp. 335–353, 2004. View at Scopus
  45. J. van der Greef and R. N. McBurney, “Rescuing drug discovery: in vivo systems pathology and systems pharmacology,” Nature Reviews Drug Discovery, vol. 4, no. 12, pp. 961–967, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Ideker, T. Galitski, and L. Hood, “A new approach to decoding life: systems biology,” Annual Review of Genomics and Human Genetics, vol. 2, pp. 343–372, 2001.
  47. H. Kitano, “Computational systems biology,” Nature, vol. 420, pp. 206–210, 2002.
  48. C. P. Adams and V. V. Brantner, “Estimating the cost of new drug development: is it really 802 million dollars?” Health Affairs, vol. 25, pp. 420–428, 2006.
  49. M. Dickson and J. P. Gagnon, “The cost of new drug discovery and development,” Discovery Medicine, vol. 4, pp. 172–179, 2004.
  50. I. Kola and J. Landis, “Can the pharmaceutical industry reduce attrition rates?” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 711–715, 2004. View at Scopus
  51. K. I. Kaitin, “Obstacles and opportunities in new drug development,” Clinical Pharmacology and Therapeutics, vol. 83, pp. 210–212, 2008.
  52. T. T. Ashburn and K. B. Thor, “Drug repositioning: identifying and developing new uses for existing drugs,” Nature Reviews Drug Discovery, vol. 3, no. 8, pp. 673–683, 2004. View at Scopus
  53. Y. Z. Chen and D. G. Zhi, “Ligand-protein inverse docking and its potential use in the computer search of protein targets of a small molecule,” Proteins, vol. 43, pp. 217–226, 2001.
  54. Y. Y. Li, J. An, and S. J. Jones, “A large-scale computational approach to drug repositioning,” Genome Informatics, vol. 17, no. 2, pp. 239–247, 2006.
  55. E. Dubus, I. Ijjaali, O. Barberan, and F. Petitet, “Drug repositioning using in silico compound profiling,” Future Medicinal Chemistry, vol. 1, no. 9, pp. 1723–1736, 2009. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Lu, Q. Zha, A. Chang, Y. He, and A. Lu, “Pattern differentiation in Traditional Chinese Medicine can help define specific indications for biomedical therapy in the treatment of rheumatoid arthritis,” Journal of Alternative and Complementary Medicine, vol. 15, pp. 1021–1025, 2009.
  57. C. Lu, C. Xiao, G. Chen et al., “Cold and heat pattern of rheumatoid arthritis in traditional Chinese medicine: distinct molecular signatures indentified by microarray expression profiles in CD4-positive T cell,” Rheumatology International, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. C. L. Miao Jiang, G. Chen, C. Xiao, et al., “Understanding the molecular mechanism of interventions in treating rheumatoid arthritis patients with corresponding traditional Chinese medicine patterns based on bioinformatics approach,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 129452, 11 pages, 2012. View at Publisher · View at Google Scholar